Back to Search Start Over

An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma.

An orthotopic syngeneic mouse model of bortezomib‐resistant multiple myeloma.

Authors :
Li, Manjun
Bennett, Melissa K.
Toubia, John
Pope, Victoria S.
Tea, Melinda N.
Tamang, Sarah
Samuel, Michael S.
Anderson, Paul H.
Gliddon, Briony L.
Powell, Jason A.
Pitson, Stuart M.
Source :
British Journal of Haematology; Feb2024, Vol. 204 Issue 2, p566-570, 5p
Publication Year :
2024

Abstract

Summary: While bortezomib has significant benefits in multiple myeloma (MM) therapy, the disease remains incurable due to the invariable development of bortezomib resistance. This emphasises the need for advanced models for preclinical evaluation of new therapeutic approaches for bortezomib‐resistant MM. Here, we describe the development of an orthotopic syngeneic bortezomib‐resistant MM mouse model based on the most well‐characterised syngeneic MM mouse model derived from spontaneous MM‐forming C57BL/KaLwRij mice. Using bortezomib‐resistant 5TGM1 cells, we report and characterise a robust syngeneic mouse model of bortezomib‐resistant MM that is well suited to the evaluation of new therapeutic approaches for proteasome inhibitor‐resistant MM. [ABSTRACT FROM AUTHOR]

Details

Language :
English
ISSN :
00071048
Volume :
204
Issue :
2
Database :
Complementary Index
Journal :
British Journal of Haematology
Publication Type :
Academic Journal
Accession number :
175303685
Full Text :
https://doi.org/10.1111/bjh.19240